

Variable	Baseline	Week.4	Week.8	Week.12	Week.16	Week.20	Week.24
SDAI							
All							
N	7	6	5	3	3	2	2
Mean	39.876	32.187	26.746	17.107	25.313	17.825	18.715
Std. Dev.	15.878	11.921	10.455	5.04	10.777	6.413	4.83
Min	17.87	18.37	14.03	12.1	16.18	13.29	15.3
1st Qu.	33.44	22.425	20.01	14.57	19.37	15.557	17.008
Median	37.1	31.605	26.75	17.04	22.56	17.825	18.715
3rd Qu.	43.68	42.382	31.94	19.61	29.88	20.093	20.422
Max	69.92	46.2	41	22.18	37.2	22.36	22.13
Anifrolumab							
N	4	3	2	1	1	1	1
Mean	46.66	29.657	22.985	17.04	22.56	13.29	15.3
Std. Dev.	16.139	13.24	12.664	NA	NA	NA	NA
Min	34.56	18.37	14.03	17.04	22.56	13.29	15.3
1st Qu.	36.465	22.37	18.508	17.04	22.56	13.29	15.3
Median	41.08	26.37	22.985	17.04	22.56	13.29	15.3
3rd Qu.	51.275	35.3	27.463	17.04	22.56	13.29	15.3
Max	69.92	44.23	31.94	17.04	22.56	13.29	15.3
Placebo							
N	3	3	3	2	2	1	1
Mean	30.83	34.717	29.253	17.14	26.69	22.36	22.13
Std. Dev.	12.283	12.679	10.717	7.128	14.863	NA	NA
Min	17.87	21.11	20.01	12.1	16.18	22.36	22.13
1st Qu.	25.095	28.975	23.38	14.62	21.435	22.36	22.13
Median	32.32	36.84	26.75	17.14	26.69	22.36	22.13
3rd Qu.	37.31	41.52	33.875	19.66	31.945	22.36	22.13
Max	42.3	46.2	41	22.18	37.2	22.36	22.13

Supplementary Table 3

Descriptive statistics for SDAI at each time point over the course of the study.